https://beonemedaffairs.kinsta.cloud/congress-resource/8193/memo-inhaematology-eha2024-congress-report/ 2025-05-26T13:49:00+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8197/memo-inhaematology-special-issue-congress-report-eha2024/ 2025-05-26T14:01:00+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8185/nma-comparison-of-efficacy-between-btkis-in-high-risk-r-r-cll/ 2025-05-26T15:12:47+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8180/maic-comparison-of-efficacy-between-btkis-in-r-r-cll/ 2025-05-26T15:14:03+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8202/satellite-symposium-the-data-behind-your-treatment-selection-in-chronic-lymphocytic-leukemia-cll-indolent-lymphomas/ 2025-05-28T06:34:51+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8205/satellite-symposium-all-you-need-to-know-when-managing-cll-or-indolent-lymphoma-patients-under-btki-treatment/ 2025-05-28T06:36:16+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8432/serious-infections-in-patients-with-cll-sll-treated-with-combination-venetoclax-and-obinutuzumab-compared-with-those-treated-with-zanubrutinib-a-real-world-study/ 2025-06-12T04:00:30+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8431/real-world-zanubrutinib-treatment-patterns-in-mantle-cell-lymphoma-among-us-community-oncology-patients-with-prior-bruton-tyrosine-kinase-inhibitor-therapy/ 2025-06-12T04:00:48+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8430/real-world-comparative-effectiveness-of-first-line-bruton-tyrosine-kinase-inhibitors-in-patients-with-chronic-lymphocytic-leukemia/ 2025-06-12T04:00:19+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8429/risk-of-hypertension-in-patients-newly-diagnosed-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-and-treated-with-covalent-bruton-tyrosine-kinase-inhibitors-a-real-world-study/ 2025-06-12T04:00:55+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8428/final-analysis-of-a-phase-1-study-of-zanubrutinib-zanu-plus-lenalidomide-len-in-patients-pts-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/ 2025-06-12T04:00:13+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8427/real-world-treatment-utilization-patterns-discontinuation-and-healthcare-resource-utilization-of-first-line-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-age-related-disparity/ 2025-06-12T04:00:45+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8426/comparative-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-a-matching-adjusted-indirect-comparison-maic/ 2025-06-12T04:00:15+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8425/real-world-burden-of-disease-treatment-patterns-and-outcomes-in-patients-with-mantle-cell-lymphoma-mcl/ 2025-06-12T04:00:36+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8424/combination-of-zanubrutinib-zanu-venetoclax-ven-for-treatment-naive-tn-cll-sll-results-in-sequoia-arm-d/ 2025-06-12T04:00:58+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8423/sequoia-5-year-follow-up-in-arm-c-frontline-zanubrutinib-monotherapy-in-patients-with-del17p-and-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll/ 2025-06-12T04:00:59+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8422/updated-interim-results-of-sonrotoclax-dexamethasone-in-patients-with-t1114-positive-relapsed-refractory-multiple-myeloma-an-all-oral-treatment/ 2025-06-12T04:00:44+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8420/updated-safety-and-antileukemic-activity-data-for-sonrotoclax-bgb-11417-a-potent-and-selective-bcl2-inhibitor-in-patients-with-relapsed-refractory-acute-myeloid-leukemia/ 2025-06-12T04:00:18+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8419/primary-analysis-results-of-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-b-cell-malignancies/ 2025-06-12T04:00:07+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8418/updated-safety-and-efficacy-results-of-a-phase-1-study-of-the-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-for-relapsed-refractory-waldenstroms-macroglobulinemia/ 2025-06-12T04:00:14+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8405/sonrotoclax-monotherapy-for-treatment-of-patients-with-relapsed-refractory-cll-data-from-an-ongoing-phase-1-1b-study-bgb-11417-101/ 2025-06-12T04:00:11+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8443/updated-efficacy-and-safety-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-pts-with-relapsed-or-refractory-r-r-cll-sll-results-from-the-ongoing-phase-ph-1-cadance-101-study/ 2025-06-14T16:39:13+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8442/updated-efficacy-safety-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-with-relapsed-refractory-waldenstrom-macroglobulinemia-wm-ongoing-phase-1-cadance-101-study-results/ 2025-06-14T16:39:43+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8444/updated-results-from-the-phase-1-study-of-sonrotoclax-bgb-11417-a-novel-bcl2-inhibitor-in-combination-with-zanubrutinib-for-relapsed-refractory-cll-sll-show-deep-and-durable-responses/ 2025-06-14T16:40:18+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8440/combination-treatment-with-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-and-zanubrutinib-induces-high-rate-of-complete-remission-for-patients-with-relapsed-refractory-mantle-cell-lymphoma/ 2025-06-17T15:14:23+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8208/satellite-symposium-improving-outcomes-for-cll-patients-from-promising-research-to-current-advances-in-daily-practice/ 2025-07-15T09:44:05+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8516/navigating-treatment-selection-and-infection-management-in-cll-summary/ 2025-08-07T15:02:37+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8523/panel-discussion-addressing-key-questions-in-cll-management-all-faculty/ 2025-08-07T15:02:52+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8522/managing-infection-risks-in-cll-helen-parry/ 2025-08-07T15:03:07+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8521/factors-influencing-individualized-treatment-selection-in-cll-anne-sophie-michallet/ 2025-08-07T15:03:19+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/7806/navigating-treatment-selection-and-infection-management-in-cll/ 2025-08-08T14:04:29+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8421/updated-safety-antileukemic-activity-data-of-sonrotoclax-bgb-11417-a-potent-and-selective-bcl2-inhibitor-in-treatment-naive-patients-with-acute-myeloid-leukemia-unfit-for-intensive-chemotherapy/ 2025-09-19T13:58:32+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8461/satellite-symposium-btk-targeting-across-lymphomas-the-key-to-effective-treatment-today-and-tomorrow/ 2025-09-19T14:54:50+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8638/a-network-meta-analysis-nma-of-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-in-treatment-naive-tn-chronic-lymphocytic-leukemia-cll/ 2025-10-20T13:51:44+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8641/combination-of-zanubrutinib-venetoclax-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-results-in-sequoia-arm-d/ 2025-10-20T13:51:52+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8635/comparative-efficacy-of-zanubrutinib-versus-fixed-duration-acalabrutinib-plus-venetoclax-for-first-line-treatment-of-chronic-lymphocytic-leukemia-cll-a-matching-adjusted-indirect-comparison-maic-2/ 2025-10-20T13:51:58+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8632/estimating-the-cardiac-deaths-associated-with-treating-chronic-lymphocytic-leukemia-with-ibrutinib-versus-zanubrutinib-in-the-united-states/ 2025-10-20T13:52:04+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8647/safety-and-efficacy-of-zanubrutinib-in-a-subgroup-of-older-patients-%e2%89%a575-years-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-from-the-sequoia-study/ 2025-10-20T13:52:11+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/8644/sequoia-5-year-follow-up-in-arm-c-frontline-zanubrutinib-monotherapy-in-patients-with-del17p-and-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/ 2025-10-20T13:52:20+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9070/cadance-104-an-ongoing-open-label-phase-1b-2-master-protocol-study-of-bruton-tyrosine-kinase-degrader-bgb-16673-in-combination-with-other-agents-in-patients-with-relapsed-refractory-b-cell-malignan/ 2025-12-06T13:00:15+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9068/a-phase-3-randomized-open-label-multicenter-study-of-sonrotoclax-bgb-11417-plus-anti-cd20-antibody-therapies-vs-venetoclax-plus-rituximab-in-patients-with-relapsed-refractory-chronic-lymphocytic/ 2025-12-06T13:00:16+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9067/sustained-efficacy-of-zanubrutinib-zanu-vs-bendamustine-rituximab-br-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-sll-cll-with-continued-favorable-survival-in/ 2025-12-06T13:00:17+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9066/long-term-results-of-patients-receiving-zanubrutinib-in-the-phase-3-alpine-study-confirm-sustained-benefit-of-zanubrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-or-small-ly/ 2025-12-06T13:00:18+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9062/preliminary-results-from-a-phase-1-1b-first-in-human-study-of-bgb-21447-a-next-generation-bcl2-inhibitor-in-patients-with-b-cell-non-hodgkin-lymphoma/ 2025-12-06T13:00:28+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9060/real-world-treatment-patterns-and-biomarker-utilization-among-patients-aged-%e2%89%a565-years-with-cll-sll-from-2020-to-2024/ 2025-12-06T13:00:28+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9058/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-indolent-non-hodgkin-lymphoma-from-the-ongoing-phase-1-cadance-101-study/ 2025-12-07T13:00:29+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9057/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-waldenstrom-macroglobulinemia-from-the-ongoing-phase-1-cadance-101-study/ 2025-12-07T13:00:30+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9056/preliminary-efficacy-and-safety-of-the-bruton-tyrosine-kinase-degrader-bgb-16673-in-patients-with-relapsed-refractory-richter-transformation-results-from-the-ongoing-phase-1-cadance-101-study/ 2025-12-07T13:00:31+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9055/frontline-treatment-of-sonrotoclax-bgb-11417-and-zanubrutinib-for-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-demonstrates-high-undetectable-minimal-residual-disease-umrd-rat/ 2025-12-07T13:00:32+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9054/zanubrutinib-obinutuzumab-sonrotoclax-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-cll-sll-initial-results-from-an-ongoing-phase-1-1b-study-bgb-1/ 2025-12-07T13:00:32+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9053/number-needed-to-treat-to-avoid-progression-or-death-zanubrutinib-vs-other-covalent-bruton-tyrosine-kinase-inhibitors-in-relapsed-refractory-chronic-lymphocytic-leukemia/ 2025-12-07T13:00:33+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9052/patient-preferences-and-factors-affecting-patient-treatment-decisions-for-chronic-lymphocytic-leukemia-cll-in-japan/ 2025-12-07T13:00:34+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9050/impact-of-testing-for-genetic-markers-on-treatment-selection-and-clinical-outcomes-among-patients-with-chronic-lymphocytic-leukemia/ 2025-12-07T13:00:34+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9048/treatment-patterns-and-outcomes-among-patients-treated-with-second-generation-btk-inhibitors-in-cll/ 2025-12-07T13:00:40+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9046/chemo-%c2%b1-immunotherapy-remains-utilized-for-chronic-lymphocytic-lymphoma-in-the-real-world-practice-unmet-needs-treatment-patterns-and-age-disparities-in-the-united-states/ 2025-12-07T13:00:41+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9044/matching-adjusted-indirect-comparison-of-efficacy-of-zanubrutinib-vs-ibrutinib-for-the-treatment-of-relapsed-refractory-mantle-cell-lymphoma/ 2025-12-08T13:00:41+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9042/bgb-3111-218-single-arm-open-label-multicenter-study-of-the-bruton-tyrosine-kinase-btk-inhibitor-zanubrutinib-zanu-in-patients-with-cd79b-mutated-relapsed-refractory-r-r-diffuse-large-b-cell/ 2025-12-08T13:00:42+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9041/zanubrutinib-is-well-tolerated-and-effective-in-acalabrutinib-intolerant-patients-with-b-cell-malignancies-a-long-term-follow-up/ 2025-12-08T13:00:43+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9039/primary-analysis-of-a-multicenter-open-label-phase-2-study-of-sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphom/ 2025-12-08T13:00:44+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9038/zanubrutinib-venetoclax-for-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-including-patients-with-del17p-and-or-tp53-mutation-and-unmutated-immunoglobulin-heav/ 2025-12-08T13:00:45+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9037/cadance-304-a-phase-3-open-label-randomized-study-to-evaluate-the-safety-and-efficacy-of-bruton-tyrosine-kinase-degrader-bgb-16673-compared-with-pirtobrutinib-in-patients-with-relapsed-refractory-c/ 2025-12-08T13:00:47+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9035/mediators-of-racial-and-ethnic-inequities-in-access-to-front-line-therapies-for-chronic-lymphocytic-leukemia-in-the-united-states-a-real-world-evidence-study/ 2025-12-08T13:00:48+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9033/evaluation-of-factors-from-established-prognostic-models-in-patients-with-chronic-lymphocytic-leukemia-cll-treated-with-zanubrutinib-a-post-hoc-analysis-of-two-phase-3-studies-sequoia-and-alpine/ 2025-12-08T13:00:50+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9032/progression-free-survival-pfs-in-patients-with-low-health-related-quality-of-life-hrqol-treated-with-zanubrutinib-versus-ibrutinib-monotherapy-post-hoc-analysis-of-the-alpine-trial/ 2025-12-08T13:00:51+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9028/changes-in-real-world-treatment-patterns-over-time-by-patient-characteristics-and-time-burden-of-treatment-in-cll-sll/ 2025-12-08T13:00:52+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9030/real-world-treatment-patterns-and-patient-characteristics-of-venetoclax-combination-time-limited-therapy-for-chronic-lymphocytic-leukemia/ 2025-12-08T13:00:55+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9064/outcomes-during-btki-treatment-for-chronic-lymphocytic-leukemia-insights-from-remote-therapeutic-monitoring/ 2025-12-06T13:00:33+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9074/initial-phase-1b-2-study-results-with-sonrotoclax-bgb-11417-in-combination-with-carfilzomib-and-dexamethasone-in-patients-with-t1114-positive-relapsed-refractory-multiple-myeloma/ 2025-12-06T14:30:14+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9073/symptom-based-progression-free-survival-s-pfs-as-a-clinically-relevant-and-patient-centric-endpoint-in-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-results-from-the-alpine-tr/ 2025-12-07T19:30:14+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9077/final-analysis-of-the-randomized-phase-2-rosewood-study-of-zanubrutinib-obinutuzumab-vs-obinutuzumab-monotherapy-in-patients-with-relapsed-refractory-follicular-lymphoma/ 2025-12-06T17:00:12+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9076/updated-efficacy-and-safety-results-of-the-bruton-tyrosine-kinase-btk-degrader-bgb-16673-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll-from-t/ 2025-12-07T20:21:08+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9078/sonrotoclax-bgb-11417-monotherapy-in-patients-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-previously-treated-with-a-bruton-tyrosine-kinase-btk-inhibitor-early-results-from-a-phase-1/ 2025-12-07T20:27:56+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9071/mrd-guided-therapy-of-sonrotoclax-bgb-11417-obinutuzumab-o-in-patients-with-treatment-naive-cll-initial-results-from-an-ongoing-phase-1-1b-study-bgb-11417-101/ 2025-12-08T15:30:15+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9136/a-curated-collection-of-visual-summaries-from-selected-beone-presentations-offering-a-concise-overview-of-study-design-efficacy-and-safety-outcomes-including-emerging-data-across-cll-and-mcl/ 2026-01-14T16:50:02+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9191/pd-results-from-first-in-human-study-of-bgb-24714-smac-mimetic-in-solid-tumors/ 2026-04-18T19:36:09+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9189/phase-3-rationale-305-biomarker-analysis-tislelizumab-chemotherapy-for-gastric-gej-cancer/ 2026-04-18T19:36:19+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9186/phase-1-bgb-24714-smac-mimetic-monotherapy-combination-with-chemotherapy-chemoradiotherapy-in-solid-tumors/ 2026-04-18T19:36:27+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9183/phase-2-study-of-tislelizumab-investigational-agents-as-first-line-treatment-in-rm-hnscc/ 2026-04-18T19:36:35+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9202/rationale-304-baseline-tumor-genomic-alterations-according-to-programmed-death-ligand-1-subgroups-in-non-squamous-non-small-cell-lung-cancer-treated-with-first-line-tislelizumab-plus-chemotherapy-vs/ 2026-04-21T10:10:08+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9208/rationale-315-association-of-residual-viable-tumor-and-nodal-status-with-survival-benefit-for-patients-with-resectable-non-small-cell-lung-cancer-treated-with-perioperative-tislelizumab/ 2026-04-21T10:10:11+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9213/pd-l1-inhibitors-for-first-line-treatment-of-extensive-stage-small-cell-lung-cancer-in-asian-and-non-asian-patients-a-meta-analysis/ 2026-04-21T10:20:11+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9216/a-comparison-of-tislelizumab-plus-chemotherapy-vs-programmed-cell-death-protein-1-pd-1-inhibitor-monotherapy-in-first-line-non-squamous-non-small-cell-lung-cancer-nsclc-patients-with-progr/ 2026-04-21T10:26:34+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9230/overview-of-the-latest-approaches-in-multidisciplinary-collaboration-for-resectable-nsclc-treatment-presented-at-elcc-2026/ 2026-04-21T10:54:59+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9232/elcc-2026-introduction/ 2026-04-21T11:00:12+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9237/which-key-factors-may-inform-the-de-escalation-escalation-of-treatment/ 2026-04-21T11:07:27+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9239/elcc-2026-discussion/ 2026-04-21T11:10:37+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9234/how-do-the-latest-data-inform-the-surgical-approach/ 2026-04-21T11:28:35+00:00 https://beonemedaffairs.kinsta.cloud/congress-resource/9253/missed-us-at-esmo-2025/ 2026-05-01T10:00:55+00:00